Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation

Karen K. Ballen, Brent R. Logan, Mary J. Laughlin, Wensheng He, Daniel R. Ambruso, Susan E. Armitage, Rachel L. Beddard, Deepika Bhatla, William Y.K. Hwang, Joseph E. Kiss, Gesine Koegler, Joanne Kurtzberg, Arnon Nagler, David Oh, Lawrence D. Petz, Thomas H. Price, Ralph R. Quinones, Voravit Ratanatharathorn, J. Douglas Rizzo, Kathleen SazamaAndromachi Scaradavou, Michael W. Schuster, Leonard S. Sender, Elizabeth J. Shpall, Stephen R. Spellman, Millicent Sutton, Lee Ann Weitekamp, John R. Wingard, Mary Eapen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Variations in cord blood manufacturing and administration are common, and the optimal practice is not known. We compared processing and banking practices at 16 public cord blood banks (CBB) in the United States and assessed transplantation outcomes on 530 single umbilical cord blood (UCB) myeloablative transplantations for hematologic malignancies facilitated by these banks. UCB banking practices were separated into 3 mutually exclusive groups based on whether processing was automated or manual, units were plasma and red blood cell reduced, or buffy coat production method or plasma reduced. Compared with the automated processing system for units, the day 28 neutrophil recovery was significantly lower after transplantation of units that were manually processed and plasma reduced (red cell replete) (odds ratio, .19; P=001) or plasma and red cell reduced (odds ratio, .54; P=05). Day 100 survival did not differ by CBB. However, day 100 survival was better with units that were thawed with the dextran-albumin wash method compared with the "no wash" or "dilution only" techniques (odds ratio, 1.82; P=04). In conclusion, CBB processing has no significant effect on early (day 100) survival despite differences in kinetics of neutrophil recovery.

Original languageEnglish
Pages (from-to)688-695
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number4
DOIs
StatePublished - 1 Apr 2015
Externally publishedYes

Funding

FundersFunder number
Allos Therapeutics, Inc.
Department of the Navy
HRSA/DHHSN00014-13-1-0039, N00014-12-1-0142
Incyte Corporation
National Institute of Health
Teva Neuroscience, Inc.
US government
National Institutes of Health
U.S. Department of Defense
Office of Naval Research
National Heart, Lung, and Blood Institute
National Cancer InstituteHHSH250201200016C, U24CA076518
National Institute of Allergy and Infectious Diseases5U10HL069294
Health Resources and Services Administration
Merck
University of Utah
Actinium Pharmaceuticals

    Keywords

    • Cord blood bank
    • Processing methods
    • Survival

    Fingerprint

    Dive into the research topics of 'Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation'. Together they form a unique fingerprint.

    Cite this